ristocetin and Lung-Diseases

Therapeutic efficacy of ristomycin in visceral actinomycosis, a severe disease difficult for diagnosis requiring long-term complex therapy was studied on 24 rabbits. The animals were divided into 4 groups. A model of thoracal actinomycosis was developed. 7 rabbits were treated with ristomycin. The other 7 rabbits were treated with ristomycin in combination with actinolysate, a specific immune preparation. 5 rabbits were treated with actinolysate alone and the other 5 rabbits received no treatment. alone and especially in combination with actinolysate was an efficient therapeutic agent for treatment of severe visceral actinomycosis. This allowed to recommend ristomycin for clinical trials in treatment of the disease.

Topics: Actinomycetales Infections; Adjuvants, Immunologic; Animals; Bacteriocins; Drug Evaluation, Preclinical; Drug Therapy, Combination; Lung; Lung Diseases; Rabbits; Ristocetin; Streptomyces; Time Factors